Issue: March 2023
Fact checked byRichard Smith

Read more

January 24, 2023
1 min read
Save

FDA approves bexagliflozin for adults with type 2 diabetes

Issue: March 2023
Fact checked byRichard Smith
You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com.

The FDA approved bexagliflozin, an oral SGLT2 inhibitor, to improve glycemic control for adults with type 2 diabetes, according to a company press release.

The approval of bexagliflozin (Brenzavvy, TheracosBio) is based on results from 23 clinical trials evaluating the safety and efficacy of bexagliflozin with more than 5,000 adults with type 2 diabetes. These trials demonstrated a significant reduction in HbA1c and fasting blood glucose with bexagliflozin treatment after 24 weeks. This treatment can be utilized as a monotherapy or combined with metformin or as an add-on to standard-of-care treatment, including metformin, sulfonylureas, insulin, DPP-IV inhibitors or combinations of all these agents, according to the release.

fdaapproval
The FDA has approved bexagliflozin, an oral SGLT2 inhibitor, for use among adults with type 2 diabetes. Source: Adobe Stock

“As a class of drugs, SGLT2 inhibitors have shown tremendous benefit in treating adults with type 2 diabetes,” Mason Freeman, MD, director of the Translational Research Center at Massachusetts General Hospital, Boston, said in the release. “Being involved in all of the clinical trials for Brenzavvy, I am greatly impressed with the efficacy of the drug in reducing blood glucose levels, and I believe it is an important addition to the SGLT2 inhibitor class of drugs.”

Bexagliflozin is approved for adults with type 2 diabetes with an estimated glomerular filtration rate greater than 30 mL/min/1.73 m2. Bexagliflozin is not recommended for patients with type 1 diabetes or for treating diabetic ketoacidosis.